Trial · NCT07221942
Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma
NCT07221942, Phase 2, Recruiting, Fox Chase Cancer Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma. Trials, record NCT07221942. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07221942
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma
- NCT number
- NCT07221942
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 97 participants, estimated
- Lead sponsor
- Fox Chase Cancer Center
- Conditions
- Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma, Advanced Urothelial Carcinoma
- Interventions
- Enfortumab vedotin, Pembrolizumab
- First posted
- 2025-10-29
- Last updated
- 2026-02-19
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 18-month progression-free survival (PFS) | 18 months | radiographic progression or death from any cause within 18 months of initiating treatment |
| Secondary | Overall Survival (OS) | 4 years | Time from initiating treatment to death from any cause, to capture long-term survival benefits |
| Secondary | Duration of Response (DoR) | 4 years | Time from first objective response (CR/PR) to radiographic progression or death, providing insight into the sustained efficacy of the treatment |
| Secondary | PFS 2 after EV rechallenge | 4 years | Since patients progressing after completing induction EV/P will be able to receive EV re-challenge, we will measure PFS with EV rechallenge measured from the start of EV rechallenge to the next progression defined by RECIST 1.1 or death |
| Secondary | Treatment-free interval | 4 years | Time from the completion of induction EV/P to either EV re-initiation or the start of another therapy, measuring how long patients remain off treatment |
| Secondary | Incidence of Peripheral neuropathy | 4 years | Changes in neuropathy-related symptoms will be assessed using the EORTC QLQ-CIPN20 survey, which evaluates sensory, motor, and autonomic neuropathy symptoms |
| Secondary | Quality of Life (QoL) using EORTC QLQ-C30 (European Organization For Research And Treatment Of Cancer Quality of Life Questionnaire) | 4 years | Assessed using EORTC QLQ-C30 questionnaire; higher scores indicate better global health status |
| Secondary | Quality of Life (QoL) using QLQ-BLM30 | 4 years | QLQ-BLM30 a disease-specific module designed to assess health-related quality of life in patients with muscle-invasive bladder cancer. Higher scores indicate more symptoms, which means a worse outcome. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07221942
GET https://conductscience.org/api/trials/v1/NCT07221942/registered